Hba1c
Adults maintain drops in body weight, HbA1c at 1 year after duodenal mucosal resurfacing
Adults with obesity and type 2 diabetes had reductions in body weight and HbA1c 1 year after undergoing an endoscopic procedure that resurfaces the duodenum lining, according to top-line results from a real-world registry study.
Spending less time in HbA1c target range may increase dementia risk for older adults
Older adults with diabetes who spend less time within their individualized HbA1c target range have a higher risk for developing Alzheimer’s disease and dementias, according to findings published in JAMA Network Open.
FDA rejects once-weekly basal insulin for diabetes, requests more information
The FDA declined to approve once-weekly basal insulin icodec for the treatment of diabetes and is requesting more information from Novo Nordisk, according to a company press release.
Sustained reduction in HbA1c for adults with type 2 diabetes after starting CGM
ORLANDO — Adults with type 2 diabetes experienced a reduction in HbA1c within 3 months of starting continuous glucose monitoring, regardless of insulin therapy, a presenter reported at the American Diabetes Association Scientific Sessions.
TIGHT: Inpatient CGM use did not improve glycemic control
ORLANDO — Adding continuous glucose monitoring to hospital standard of care does not appear to improve glycemic control for adults with type 2 diabetes, according to results of the TIGHT study.
SELECT: Semaglutide provides CV benefits for adults with obesity, regardless of HbA1c
ORLANDO — Semaglutide reduces risk for cardiovascular events among adults with overweight or obesity and preexisting cardiovascular disease, regardless of baseline HbA1c or change in HbA1c, according to data from the SELECT trial.
Inhaled insulin noninferior to usual care for adults with type 1 diabetes
ORLANDO — An inhaled insulin was noninferior to usual care for change in HbA1c and continuous glucose monitoring metrics among adults with type 1 diabetes, according to data from the INHALE-3 trial.
FDA approves dapagliflozin for children and adolescents with type 2 diabetes
The FDA approved the SGLT2 inhibitor dapagliflozin to improve glycemic control among children and adolescents aged 10 years and older with type 2 diabetes, according to an industry press release.
Relacorilant tied to sustained cardiometabolic improvements in Cushing’s syndrome
PHILADELPHIA — Adults with Cushing’s syndrome who responded to relacorilant had sustained improvements in blood pressure and glucose levels through 34 weeks, according to findings from a phase 3 trial.
Tirzepatide lowers body weight, improves glycemic control for adults with type 1 diabetes
Adults with type 1 diabetes and overweight or obesity prescribed tirzepatide off-label had a reduction in body weight and improvements in HbA1c and continuous glucose monitoring metrics, according to data from a real-world study.